XML 25 R18.htm IDEA: XBRL DOCUMENT
v3.25.3

Stock Based Compensation | 9 Months Ended
--- | ---
Sep. 30, 2025
Share-Based Payment Arrangement [Abstract] |
Stock Based Compensation |
10. | Stock Based Compensation
2023 Omnibus Incentive Plan The Gyre 2023 Omnibus Incentive Plan (the “2023 Omnibus Incentive Plan”) was approved by Catalyst’s stockholders in August 2023 and ratified by Gyre’s Board in October 2023. The 2023 Omnibus Incentive Plan became effective on October 30, 2023. The 2023 Omnibus Incentive Plan permits the Company to issue up to 17,845,496 shares of common stock and will automatically increase by the lesser of (i) 5% of the total number of outstanding shares of common stock on December 31st of the preceding calendar year and (ii) such smaller number of shares of common stock as determined by Gyre's Board on the first day of each fiscal year beginning on January 1, 2024. On January 1, 2024, pursuant to the automatic increase in the number of shares reserved, an additional 3,829,780 shares of common stock were reserved and made available for issuance under the 2023 Omnibus Incentive Plan. On January 1, 2025, pursuant to the automatic increase in the number of shares reserved, an additional 4,315,377 shares of common stock were reserved and made available for issuance under the 2023 Omnibus Incentive Pl an. During the nine months ended September 30, 2025, certain members of senior management were granted both awards subject solely to time-based vesting requirements and awards that are subject to the achievement of certain levels of specific performance, in addition to time-based vesting requirements (the “Performance-Based Awards”). These Performance-Based Awards are subject to the achievement of certain sales metrics and approval of Hydronidone for commercialization. The number of Performance-Based Awards that may vest in full after two or three years ranges. The awards become eligible to vest only if the goals are achieved and will vest only if the grantee remains employed by us through each applicable vesting date. The following table summarizes stock option activity for the nine months ended September 30, 2025:
|  | Number of Shares Underlying Outstanding Options |  |  | Weighted- Average Exercise Price |  |  | Weighted- Average Remaining Contractual Term (Years) |
Outstanding — December 31, 2024 |  |  | 18,077,869 |  |  | $ | 1.75 |  |  |  | 6.0 |
Options granted |  |  | 1,939,000 |  |  | $ | 9.68 |  |  |  |
Options exercised |  |  | (1,972,548 | ) |  | $ | 1.03 |  |  |  | 0.0 |
Options forfeited and cancelled |  |  | — |  |  |  |  |  |  |
Outstanding — September 30, 2025 |  |  | 18,044,321 |  |  | $ | 2.68 |  |  |  | 5.8 |
Exercisable — September 30, 2025 |  |  | 15,782,865 |  |  | $ | 1.68 |  |  |  | 5.2 |
Valuation Assumptions The Company estimated the fair value of time-based stock options granted using the Black-Scholes option-pricing formula and a single option award approach. Due to its limited relevant historical data, the Company estimated its volatility considering a number of factors, including the use of the volatility of comparable public companies. The expected term of options granted under the 2023 Omnibus Incentive Plan, all of which qualify as “plain vanilla” per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company’s limited relevant history. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period. The Company also granted performance-based stock options, which vest based on two independent performance conditions. One condition is tied to a performance target that is deemed probable as of September 30, 2025. The other condition is tied to the approval in the PRC of a New Drug Application (“NDA”) for Hydronidone, which is not considered probable as of September 30, 2025. The grant-date fair value of these awards was determined using the Black-Scholes Option Pricing Model, which incorporates key inputs such as stock price, strike price, expected volatility, risk-free interest rate, time to expiration, and a zero-dividend yield. The following table shows the weighted-average grant date fair value of options and the assumptions used to estimate the fair value for time-based awards, and for performance-based awards during the three and nine months ended September 30, 2025 and 2024:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
Time-based and performance-based awards |  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Weighted-average grant-date fair value |  | $ | 5.09 |  |  | $ | 7.23 |  |  | $ | 6.97 |  |  | $ | 7.25 |
Risk-free interest rate (%) |  | 3.84% - 3.91% |  |  |  | 3.7 | % |  | 3.84% - 4.40% |  |  |  | 3.7 | %
Expected option life (in years) |  | 5.81 - 6.08 |  |  |  | 5.9 |  |  | 5.27 - 6.41 |  |  |  | 5.9 |
Expected dividend yield (%) |  |  | — | % |  |  | — | % |  |  | — | % |  |  | — | %
Volatility (%) |  |  | 81.5 | % |  |  | 84.1 | % |  | 81.5% - 84.3% |  |  |  | 84.1 | %
Total stock-based compensation expense recognized was as follows (in thousands):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
General and administrative |  | $ | 1,085 |  |  | $ | 237 |  |  | $ | 2,422 |  |  | $ | 264 |
Cost of revenue |  |  | 38 |  |  |  | — |  |  |  | 85 |  |  |  | — |
Selling and marketing |  |  | 24 |  |  |  | — |  |  |  | 53 |  |  |  | — |
Total stock-based compensation expense |  | $ | 1,147 |  |  | $ | 237 |  |  | $ | 2,560 |  |  | $ | 264 |
As of September 30, 2025, the Company had an unrecognized stock-based compensation expense of $15.1 million, related to unvested stock option awards, which is expected to be recognized over an estimated weighted-average period of 3.1 years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration